AZ’ Calquence granted US Breakthrough Therapy Designation
admin 14th August 2019 Uncategorised 0The drug has been approved for chronic lymphocytic leukaemia.
More: AZ’ Calquence granted US Breakthrough Therapy Designation
Source: News
The drug has been approved for chronic lymphocytic leukaemia.
More: AZ’ Calquence granted US Breakthrough Therapy Designation
Source: News
Data favor Merck, Eisai’s Keytruda-Lenvima as the winner in kidney cancer, but window still open for Bristol Myers: analyst
Data favor Merck, Eisai’s Keytruda-Lenvima as the winner in kidney
FDA could reject AstraZeneca’s COVID vaccine on efficacy and manufacturing shortfalls: analyst
FDA could reject AstraZeneca’s COVID vaccine on efficacy and manufa
Pfizer, Moderna pledge more mRNA vaccine doses to Europe after AZ supply concerns
Pfizer, Moderna pledge more mRNA vaccine doses to Europe after AZ sup
© 1994 - 2021 B.M. Pharmaceuticals